Evidence map›Paper›PMID 39902619›Full record

ArticleAmerican journal of hematology2025

Sharpening the Tools to Get the Edge on Leukemia.

Shai Shimony, Jacqueline S Garcia

Abstract read
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shai ShimonyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7245-9652
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-2118-6302

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid LeukemiaK08CA245209 · NCI · DANA-FARBER CANCER INST · PI GARCIA, JACQUELINE SUEN · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA245209NCI NIH HHS P01 CA066996NIH HHS CA066996NIH HHS K08CA245209
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39902619
PMCPMC11968204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.